Zirconium silicate

Drug Profile

Zirconium silicate

Alternative Names: Lokelma; Sodium zirconium cyclosilicate; UXSi-9; Ziconite; Zircon; ZS; ZS 9

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ZS Pharma
  • Class Heavy metals; Minerals; Silicates; Transition elements
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hyperkalaemia

Most Recent Events

  • 17 Mar 2017 ZS Pharma receives complete response letter from the FDA for zirconium silicate in Hyperkalaemia
  • 24 Feb 2017 AstraZeneca expects regulatory decision by the TGA and US-FDA for filings for Hyperkalaemia in the first half of 2017
  • 23 Feb 2017 CHMP recommends approval of zirconium silicate for Hyperkalaemia in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top